ProPhase Labs, Inc. (Formerly Known as Quigley Corporation)

121 articles about ProPhase Labs, Inc. (Formerly Known as Quigley Corporation)

• Quigley Corporation to Present at NYSSA Biotech/Specialty Pharma Conference

  12/7/2007

• Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy

  9/11/2007

• Quigley Corporation Retains CRT Capital Group LLC as Financial Advisor and Investment Banker

  5/1/2007

• Quigley Corporation Reports First Quarter Results; Increases Investment in Pharmaceutical R&D Future

  4/26/2007

• Quigley Corporation QR-443 Cachexia Compound Demonstrates Dose Response Effectiveness In Second Preliminary Animal Model Study; Oral Dosing Of QR-443 Equally Effective To Intra-Peritoneal Administration In Delaying The Progression Of Cachexia In Prelimina

  1/22/2007

• Quigley Corporation Herpes Treatment QR-435 Fails In Animal Testing

  12/28/2006

• The Quigley Corporation To Present At NYSSA Biotech/Specialty Pharma Conference

  12/6/2006

• Quigley Corporation Reports Third Quarter Results; Continues To Invest For The Future In Pharmaceutical R&D

  10/26/2006

• Quigley Corporation Launches Redesigned Quigley Pharma Web Site; Web Site Engages Strategic Partners And Stock Holders With View On Holistic Approach To Pharmaceutical Development

  8/28/2006

• Quigley Corporation Reports Second Quarter Results - Continues Its Investing For The Future In Pharmaceutical R&D -

  7/27/2006

• Quigley Pharma Inc. Announces Continued Progress In Natural Broad Spectrum Anti-Viral For Use In Preventing Spread Of Avian Flu In Poultry Stocks

  7/19/2006

• The Quigley Corporation Reports First Quarter Results; Continues Its Investing For The Future In Pharmaceutical R&D

  4/27/2006

• Quigley Pharma Inc. Initiates Development Plan To Test QR-441(A) Against Avian Flu in Poultry Stocks Company Enlists Industry Experts To Assist In The Design Of INAD (Investigational New Animal Drug) Bird Challenge Studies

  3/21/2006

• Quigley Corporation Submits Investigational New Drug Application To The Quigley Pharma Inc. For Its QR-333 Diabetic Peripheral Neuropathy Compound; Filing Allows Quigley Corporation To Begin Human Clinical Trials Following A 30-Day Review Period

  3/7/2006

• FDA Issues Investigational New Animal Drug (INAD) Number To Quigley Pharma Inc. To Study Its Anti-Inflammatory Compound QR-440 On Arthritis In Dogs

  1/31/2006

• Quigley Corporation Amends Third Quarter Results

  11/15/2005

• Quigley Corporation Retains Brocair Partners LLC To Provide Strategic Option Evaluations For Quigley Pharma's QR-340 Scar Formula

  11/3/2005

• Quigley Corporation Reports Third Quarter Results

  10/27/2005

• The Quigley Corporation Announces Results Of Animal Model Inflammation Studies Of Its QR440 Botanical, Anti-Inflammatory Compound

  6/28/2005

• Quigley Pharma Announces Research And Development Update

  1/24/2005